CTRI/2020/07/026791已完成2 期
A Randomised Control Trial of Statin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection (RESIST Trial) - RESIST Trial
Dr Deepti Siddharthan0 个研究点目标入组 900 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) RT-PCR positive for SARS-CoV-19 infection,
- •2)Symptoms (WHO clinical improvement ordinal score 3 to 5) requiring hospital admission,
- •3)Consenting to participate for the trial.
排除标准
- •1) Critical illness with WHO clinical improvement ordinal score >5,
- •2) Documented significant liver disease / dysfunction (AST/ALT > 240),
- •3) Myopathy and Rhabdomyolysis (CPK > 5x normal),
- •4) Allergy or intolerance to statins,
- •5) Allergy or intolerance to aspirin,
- •6) Patients taking the following medications: cyclosporine, HIV protease inhibitors, hepatitis C protease inhibitor, telaprevir, fibric acid derivatives (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole) clarithromycin and colchicine,
- •7) Prior statin use (within 30 days),
- •8) Prior aspirin use (within 30 days),
- •9) History of active GI bleeding in past three months,
- •10)Coagulopathy,
- •11)Thrombocytopenia (Platelet count < 100000/ dl),
- •12)Pregnancy, active breast-feeding,
- •13)Patient unable to take oral or nasogastric medications.
研究者
相似试验
尚未招募
2 期
Effect of addition of aspirin in cervical cancer survivalCTRI/2024/04/065470Department of Surgical Oncology
尚未招募
2 期
effect of addition of Aspirin in oral cancer survivalCTRI/2023/05/052737Banaras Hindu University
进行中（未招募）
1 期
A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa - RCT of Atorvastatin in Bronchiectasis in patients with PseudomonasThe aim of this randomized double blind controlled study is to evaluate the efficacy of a 3 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis.MedDRA version: 14.1Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022042-24-GBHS Lothian32
进行中（未招募）
1 期
A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis - Randomised Controlled Trial of Atorvastatin in BronchiectasisThe aim of this randomised double blind controlled study to evaluate the efficacy of 6 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasisMedDRA version: 14.1 Level: PT Classification code 10006445 Term: Bronchiectasis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022040-20-GBHS Lothian60
招募中
3 期
The effect of adding Nicorandil to the three-drug regimen on the quality of life in patients with Coronary slow blood flow diseaseIRCT20221228056964N1Qazvin University of Medical Sciences56